The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy
Open accessAbstract
We investigated the effect of the angiotensin type 1 (AT-1) receptor antagonist, irbesartan, on matrix metalloproteinase (MMP) activity and cardiac cytokines in an animal model of diabetic cardiomyopathy. Diabetes was induced in 20 C57/bl6 mice by injection of streptozotocin (STZ). These animals were treated with irbesartan or placebo and were compared with nondiabetic controls. Left ventricular (LV) function was measured by pressure-volume loops with parameters for systolic function (end systolic elastance [Ees]) and diastolic function (cardiac stiffness) 8 weeks after STZ treatment. The cardiac protein content of interleukin (IL)1β and transforming growth factor (TGF)β1 were measured by enzyme-linked immunosorbent assay. The total cardiac collagen content and collagen type 1 and 3 were measured by histochemestry, and MMP-2 activity was measured by gelatin zymography. LV dysfunction was documented by impaired Ees and diastolic stiffness in STZ mice compared with controls. This was accompanied by increased TGFβ, IL1β, and fibrosis and decreased MMP-2 activity. Treatment with irbesartan attenuated LV dysfunction, IL1β, TGFβ, and cardiac fibrosis compared with untreated diabetic animals and normalized MMP activity. These findings present evidence that AT-1 receptor antagonists attenuate cardiac failure by decreasing cardiac inflammation and normalizing MMP activity, leading to normalized cardiac fibrosis in STZ-induced diabetic cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
Role of diabetes in congestive heart failure: The Framingham study
Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974) · The American Journal of Cardiology · doi:10.1016/0002-9149(74)90089-7 · Cited by 2,090
Controlling TGF-beta signaling.
Massagué, J., & Chen, Y. (2000) · PubMed · Cited by 1,780
Massagué, J., & Chen, Y.-G. (2000) · Genes & Development · doi:10.1101/gad.14.6.627 · Cited by 1,575
Torre-Amione, G., Kapadia, S., Benedict, C., Oral, H., Young, J. B., & Mann, D. L. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00589-7 · Cited by 1,211
Inflammatory Cytokines and Postmyocardial Infarction Remodeling
Nian, M., Lee, P., Khaper, N., & Liu, P. (2004) · Circulation Research · doi:10.1161/01.res.0000130526.20854.fa · Cited by 1,028
Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications
Fang, Z. Y., Prins, J. B., & Marwick, T. H. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0012 · Cited by 912
Zile, M. R., & Brutsaert, D. L. (2002) · Circulation · doi:10.1161/hc1202.105290 · Cited by 887
Schönbeck, U., Mach, F., & Libby, P. (1998) · PubMed · Cited by 681
Schönbeck, U., Mach, F., & Libby, P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3340 · Cited by 595
Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor
McGeehan, G. M., Becherer, J. D., Bast, R. C., Boyer, C. M., Champion, B., Connolly, K. M., Conway, J. G., Furdon, P., Karp, S., Kidao, S., et al. (1994) · Nature · doi:10.1038/370558a0 · Cited by 561
Adaptation and Maladaptation of the Heart in Diabetes: Part I: General Concepts
Taegtmeyer, H., McNulty, P., & Young, M. E. (2002) · Circulation · doi:10.1161/01.cir.0000012466.50373.e8 · Cited by 521
The role of tumor necrosis factor in the pathophysiology of heart failure
Feldman, A. M., Combes, A., Wagner, D., Kadakomi, T., Kubota, T., You Li, Y., & McTiernan, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00600-2 · Cited by 506
Characterization of Susceptibility of Inbred Mouse Strains to Diabetic Nephropathy
Qi, Z., Fujita, H., Jin, J., Davis, L. S., Wang, Y., Fogo, A. B., & Breyer, M. D. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2628 · Cited by 297
Trost, S. U., Belke, D. D., Bluhm, W. F., Meyer, M., Swanson, E., & Dillmann, W. H. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1166 · Cited by 261
Dzau, V. J., Bernstein, K., Celermajer, D., Cohen, J., Dahlöf, B., Deanfield, J., Diez, J., Drexler, H., Ferrari, R., van Gilst, W., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01878-1 · Cited by 259
Self-citationCollagen remodelling in myocardia of patients with diabetes.
Shimizu, M., Umeda, K., Sugihara, N., Yoshio, H., Ino, H., Takeda, R., Okada, Y., & Nakanishi, I. (1993) · Journal of Clinical Pathology · doi:10.1136/jcp.46.1.32 · Cited by 247
Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis
Candido, R., Allen, T. J., Lassila, M., Cao, Z., Thallas, V., Cooper, M. E., & Jandeleit-Dahm, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000124061.78478.94 · Cited by 195
Angiotensin II as a pro-inflammatory mediator.
Phillips, M. I., & Kagiyama, S. (2002) · PubMed · Cited by 183
Matrix Metalloproteinases and Diabetic Vascular Complications
Kadoglou, N. P. E., Daskalopoulou, S. S., Perrea, D. N., & Liapis, C. D. (2005) · Angiology · doi:10.1177/000331970505600208 · Cited by 166
Westermann, D., Rutschow, S., Linthout, S. V., Linderer, A., Bücker-Gärtner, C., Sobirey, M., Riad, A. H., Pauschinger, M., Schultheiß, H., & Tschöpe, C. (2006) · Diabetologia · doi:10.1007/s00125-006-0385-2 · Cited by 156
Self-citationLitwin, S. E., Raya, T. E., Anderson, P. G., Daugherty, S., & Goldman, S. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114734 · Cited by 124
Tschöpe, C., Walther, T., Escher, F., Spillmann, F., Du, J., Altmann, C., Schimke, I., Bäder, M., Sánchez‐Ferrer, C. F., Schultheiß, H., et al. (2005) · The FASEB Journal · doi:10.1096/fj.05-4095fje · Cited by 124
Myocardial proteases and matrix remodeling in inflammatory heart disease
Rutschow, S., LI, J., Schultheiss, H., & Pauschinger, M. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.009 · Cited by 114
Self-citationVetter, R., Rehfeld, U., Reißfelder, C., Weiß, W., Wagner, K., Günther, J., Hammes, A., Tschöpe, C., DILLMANN, W. H., & Paul, M. (2002) · The FASEB Journal · doi:10.1096/fj.01-1019fje · Cited by 106
Westermann, D., Knollmann, B. C., Paul Steendijk, A., Rutschow, S., Riad, A., Pauschinger, M., Potter, J. D., Schultheiss, H., & Tschöpe, C. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.07.012 · Cited by 84
Self-citationSun, Y., Zhang, J., Lu, L., Bedigian, M. P., Robinson, A., & Weber, K. T. (2004) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2003.07.004 · Cited by 82
Asbún, J., Manso, A. M., & Villarreal, F. J. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00340.2004 · Cited by 79
Early molecular events in the development of the diabetic cardiomyopathy
Moenkemann, H., Vriese, A. S. D., Blom, H. J., Kluijtmans, L. A. J., Heil, S. G., Schild, H. H., & Golubnitschaja, O. (2002) · Amino Acids · doi:10.1007/s00726-001-0146-y · Cited by 58
Cardiomyocyte Dysfunction in Models of Type 1 and Type 2 Diabetes
Kralik, P. M., Ye, G., Metreveli, N. S., Shen, X., & Epstein, P. N. (2005) · Cardiovascular Toxicology · doi:10.1385/ct:5:3:285 · Cited by 50
Tissue-Specific Regulation of Growth Factors and Clusterin by Angiotensin II
YOO, K., Thornhill, B. A., Wolstenholme, J. T., & Chevalier, R. L. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(98)00018-1 · Cited by 49
Angiotensin stimulates TGF-β1 and clusterin in the hydronephrotic neonatal rat kidney
Yoo, K. H., Thornhill, B. A., & Chevalier, R. L. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.3.r640 · Cited by 30
Tayebjee, M. H., Lip, G. Y. H., & MacFadyen, R. J. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01675.x · Cited by 28
Irbesartan inhibits human T‐lymphocyte activation through downregulation of activator protein‐1
Cheng, S., Yang, S., Ho, L., Tsao, T., Chang, D., & Lai, J. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705785 · Cited by 21
Cited by
Molecular mechanisms of diabetic cardiomyopathy
Bugger, H., & Abel, E. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3171-6 · Cited by 903
Basic Mechanisms of Diabetic Heart Disease
Ritchie, R. H., & Abel, E. D. (2020) · Circulation Research · doi:10.1161/circresaha.120.315913 · Cited by 708
Westermann, D., Lindner, D., Kasner, M., Zietsch, C., Savvatis, K., Escher, F., von Schlippenbach, J., Skurk, C., Steendijk, P., Riad, A., et al. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.931451 · Cited by 644
Self-citationHuynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 553
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
Metadata
- Authors
- Westermann, D., Rutschow, S., Jäger, S., Linderer, A., Anker, S., Riad, A., Unger, T., Schultheiss, H.-P., Pauschinger, M., & Tschöpe, C.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-03-01
- Volume
- 56
- Issue
- 3
- Pages
- 641-646
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2111475173
- Cited by
- 273
- References
- 34
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.